Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy

Journal of Medical Virology

Volumn 59, Issue 3, 1999, Pages 263-269

  Yeo, Winnie ^a   Steinberg, Joyce L ^a   Tam, John S ^a   Chan, Paul K S ^a   Leung, Nancy W Y ^a   Lam, Kwok C ^a   Mok, Tony S K ^a   Johnson, Philip J ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cytotoxic chemotherapy; HBV reactivation; Lamivudine

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE;

ADULT; ARTICLE; CANCER PATIENT; CANCER SCREENING; CLINICAL ARTICLE; CYTOTOXICITY; DRUG EFFECT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FUNCTION TEST; MALE; SEROCONVERSION; VIRUS CARRIER; VIRUS REACTIVATION; VIRUS REPLICATION;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME; VIRUS ACTIVATION;

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 0032833173     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199911)59:3<263::AID-JMV1>3.0.CO;2-X     Document Type: Article

References (33)

1. Alexander GJM, Nouriaria K, Eddleston ALWF, Williams R. 1983. Contrasting relations between suppressor-cell number in chronic liver disease. Lancet 1:1291-1293.
2. Andreone P, Caraceni P, Grazi GL, Belli L, Milandri GL, Ercolani G, Jovine E, D'Errico A, Dal Monte PR, Ideo G, Forti D, Mazziotti A, Cavallari A, Bernardi M. 1998. Lamivudine treatment for acute hepatitis B after liver transplantation. J Hepatol 29:985-989.
3. Atkins M, Hunt CM, Brown N, Gray F, Sanathanan L, Woessner M, Lai C, Dusheiko G, Dienstag J, Wright T, Barnard J, Bourne E, Condreay L. 1998. Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients. Hepatol 28(4 part 2):abst 625.
4. Benhanmou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, Tubiana R, Herson S, Poynard T, Opolon P. 1996. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 125:705-712.
5. Borg FT, Smorenburg S, De Man RA, Rietbroek RC, Chamuleau RAFM, Jones EA. 1998. Recovery from life-threatening corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy. Dig Dis Sci 43:2267-2270.
6. Chang CN, Skalski V, Zhou JH, Cheng YC. 1992. Biochemical pharmacology of (+)- and (-)2′,3′-dideoxy-3′3 thiacytidine as anti-hepatitis B virus agents. J Biol Chem 67:22414-22420.
7. Clark FL, Drummond MW, Chambers S, Chapman BA, Patton WN. 1998. Siccessful treatment of lamivudine for fulminant hepatitis B infection following intensive therapy for high grade non-Hodgkin's lymphoma. Ann Oncol 9:385-387.
8. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657-1661.
9. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. 1993. Inhibition of the replication of hepatitis B virus in vitro by (-)2′,3′-dideoxy-3′3thiacytidine, results in a rapid suppression of hepaviral DNA in sera. Clin Invest Med 16(suppl 4):B77.
10. + cells per cubic millimeter. N Engl J Med 333:1662-1669.
11. Fontana RJ, Lok ASF. 1997. Combination therapy for chronic hepatitis B. Hepatology 26:234-237.
12. Galbraith RM, Eddleston AL, Williams R, Zuckerman AW, Bagshawe KD. 1975. Fulminating hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 2:528-530.
13. Hanson RG, Peters MG, Hoofnagle JH. 1986. Effects of immunosuppressive therapy with prednisolone on B and T cell function in patients with chronic type B hepatitis. Hepatology 6:173-179.
14. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones A, Micetich K, Young R, Costa J. 1982. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96:447-449.
15. Junk YO, Lee YS, Yang WS, Han DJ, Park JS, Park SK. 1998. Treatment of chronic hepatitis B with lamivudine in renal transplant recipients. Transplantation 66:733-737.
16. Kane MA. 1983. Progress on the control of hepatitis B infection through immunization. Gut 34(suppl 2):S10-12.
17. Lai CL, Ching CK, Tung AKM, Li E, Young J, Hill A, Wong BCY, Dent J, Wu PC. 1997. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 25:241-244.
18. Lai CL, Chien RN , Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent J, Barber J, Stephenson SL, Gray DF. 1998. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339:61-68.
19. Lau JYN, Lai CL, Lin HJ, Lok ASF, Liang RHS, Wu PC, Chan TK, Todd D. 1989. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 73:911-917.
20. Lau JYN, Bird GLA, Gimson AES, Alexander GJM, Williams R. 1991. Treatment of HBV reactivation after withdrawal of immunosuppression. Lancet 337:802.
21. Liang RHS, Lok ASF, Lai CL, Chan TK, Todd O, Chiu EKW. 1990. Hepatitis B infection in patients with lymphomas. Hematol Oncol 8:261-270.
22. Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Todd D. 1991. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182-188.
23. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, Goss JA, Schmidt P, Pakrasi A, Artinian L, Murray NGB, Imagawa DK, Holt C, Goldstein LI, Stribling R, Busuttil RW. 1998. Prophylaxis against hepatitis B recurrence following liver transplantation using combination of lamivudine and hepatitis B immune globulin. Hepatology 28:585-589.
24. Mondelli M, Vergani GM, Albert A, Vergani D, Portmann B, Eddleston AC, Williams R. 1992. Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol 129.2273-2278.
25. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, De Man RA, Thomas HC. 1997. Lamivudine therapy for chronic hepatitis B: a six-month randomised dose-ranging study. Gastroenterology 113:1258-1263.
26. Perrillo RP. 1990. Factors influencing response to interferon in chronic hepatitis B: implications for Asian and western populations. Hepatobgy 12:1433-1435.
27. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC, Lindsay K, Payne J, Dienstag JC, O'Brien C, Tamburro C, Jacabson IM. 1990. A randomised, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment hepatitis B. N Engl J Med 323:295-301.
28. Pinto PC, Hu E, Bernstein-Singer M, Pinter-Brown L, Govindarajan S. 1990. Acute hepatic injury after withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 65:878-884.
29. Schalm SW, de Man RA, Heijtink RA, Neisters HGM. 1995. New nucleoside analogues for chronic hepatitis B infection. J Hepatol 22(suppl 1):52-56.
30. Soh LT, Ang PT, Sng I, Chua EJ, Ong Y. 1992. Fulminant hepatic failure in non-Hodgkin's lymphoma patients treated with chemotherapy. Eur J Cancer 28A:1338.
31. Tassopoulas NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin R, Hawley S, Gray DF. 1998. Lamivudine therapy in patients with anti HBe positive chronic hepatitis B; end of treatment analysis. J Hepatol 1:GS2/08.
32. Thung SN, Gerber MA, Klion F, Gilbert H. 1985. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B carrier. Arch Intern Med 145:1313-1314.
33. Wong GC, Tan P, Goh YT, Ng HS, Lee LH. 1996. Exacerbation of hepatitis B carriers following chemotherapy for haematological malignancies. Ann Acad Med Singapore 25:500-503.